Monday 06 Jul, 2020 07:20 AM
Site map | Locate Us | Login
   Sobha reports Q1 operational performance update     PVR board to meet on 6 July    National Fertilizers posts record fertilizer sale of 12.85 LMT in Q1    L&T Finance says deal to sell L&T Capital Markets (Middle East) terminated    Adani Ports records throughput of 41.5 MMT in Q1    HOEC temporarily suspends operations at PY-1 field    NLC India, Coal India form JV to develop 5,000 MW solar, thermal power assets    Marico remains cautiously optimistic amid volatile biz environment    Gati records Q4 net loss of Rs 63 cr    Indiabulls Housing Q4 PAT slump 86% to Rs 137 cr    Shriram Transport is planning to raise funds    NLC India firms up on raising Rs 500 cr via commercial papers    Omaxe Ltd leads losers in 'A' group    Edelweiss Financial gains on buzz NBFC arm sells sticky loans to global funds    Archidply Industries Ltd leads losers in 'B' group 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Alkem Labs Q4 PAT rises 13% to Rs 189 cr
06-Jun-20   11:25 Hrs IST

Consolidated profit before tax stood at Rs 235.30 in Q4 March 2020, rising 18.4% from Rs 198.81 crore in the same period last year. Total tax expenses increased 54% to Rs 43.76 crore in Q4 March 2020 over Q4 March 2019.

Consolidated EBITDA rose 29.6% to Rs 303 crore in Q4 March 2020, from Rs 2,33.80 crore in Q4 March 2019. EBITDA margin improved to 14.8% in Q4 March 2020 from 12.6% in Q4 March 2019.

During the quarter, India sales stood at Rs 1,257.60 crore (up 3.3%) and International sales stood at Rs 752.30 crore (up 23.4%).

Alkem Laboratories said R&D expenses for the quarter ending March 2020 was at Rs 125.30 crore or 6.1% of revenue from operations compared with Rs 139.20 crore at 7.5% of revenue from operations in Q4 March 2019.

Commenting on the results, Sandeep Singh, managing director, Alkem said, Adjusting for the impact of delay in transportation due to lockdown which led to a lower booking of sales in the month of March 2020, our India business delivered a healthy double digit growth during the quarter and the year. Our US business also complimented well with a robust growth on the back of new product launches and market share gains. The company's EBITDA margins improved by more than 200 bps during the quarter and the year, thereby highlighting our ongoing efforts towards cost optimization and process improvement. While FY21 has started on a challenging note due to COVID-19, we are positive that the inherent business strengths that we have built over the years in terms of strong brands, marketing and distribution infrastructure and H&U investments, will help us to navigate through these testing times and deliver a sustainable and a profitable growth.

The board recommended a dividend of Rs 3 per equity share and fixed 11 August 2020 as a record date.

Alkem Laboratories is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products. The company operates through two segments: pharmaceutical and investing.

Shares of Alkem Laboratories fell 1.92% to Rs 2395.95 on Friday. Meanwhile the S&P BSE Sensex closed 306.54 points or 0.9% higher at 34,287.24.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.G Anand , anand@ssplwealth.com
Hit Count : 14360134
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016  |  MCX : INZ000081736
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 12815 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. Saravana Stocks Pvt. Ltd